A Phase 2 interventional study of Levofloxacin and Usual Care in Myeldysplastic Syndrome (MDS), MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET) and Acute Myeloid Leukemia, sponsored by University of Manitoba. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Manitoba · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Myeloproliferative Disorders with a site in Canada — 11 open to participants now, 23 under way, 7 of them phase 3. Myeloproliferative Disorders · Canada.
Among the 58 studies in Myeloproliferative Disorders with a site in Canada, this one is the 38th largest by planned enrollment of the 54 interventional ones that give a count, is the only one that started in 2027, is one of 17 in phase 2, reaches primary completion later than 16 of the 22 other live ones, and was the 58th registered.
668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.
Browse Myeloproliferative Disorders studies →11 of the 58 studies in Myeloproliferative Disorders with a site in Canada are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in Canada, United States, Australia and 8 more countries
Ages 18+
University of Manitoba · Sites in Canada
Ages 18+
National Cancer Institute (NCI) · Sites in Canada, United States, Puerto Rico
Ages 18–59
National Cancer Institute (NCI) · Sites in Canada, United States, Puerto Rico
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 87 Myeloproliferative Disorders studies recruiting now, 63 (72%) set no upper age limit and 18 (21%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 20 · Phase 3 23 · Phase 4 1
First in 1998; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 75 is above the median of 47 across 463 interventional studies indexed under Myeloproliferative Disorders.
Median enrollment 160 across the 54 interventional studies, 2,796 across the 4 observational. Of the 34 that completed or were terminated, 19 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 58 have an industry lead sponsor. The 10 most frequent:
University of Manitoba is the lead sponsor of 555 studies on the registry; 88 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.
University of Manitoba has 2 studies filed under Myeloproliferative Disorders — fewer than ten, so there is no comparison to draw.
7 of the studies in Myeloproliferative Disorders with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468033Phase 3PharmaEssentiaP1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | 2027-11-18 |
| NCT05074355University Health Network, TorontoStudy of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms | 2026-12-31 |
| NCT05554406National Cancer Institute (NCI)Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | 2027-03-31 |
| NCT06599762University of ManitobaEvaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia | 2027-04-01 |
| NCT04279847Incyte CorporationSafety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 58 studies in Myeloproliferative Disorders with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are serious, life-changing blood cancers. Patients with MDS and AML commonly experience complications related to infection, which affect patient quality-of-life and can sometimes lead to hospitalization or death. The investigators will conduct a randomized controlled trial to evaluate the effectiveness and safety of levofloxacin (antibiotic) in MDS and AML patients to safely reduce the risk of infection. In this study 50% of patients will be randomized (like a flip of a coin) to receive levofloxacin and the other 50% will receive usual care (control). The primary objective of the trial is to demonstrate the feasibility of a pragmatic pilot trial necessary to inform our planned phase 3 trial. Additionally, the investigators will monitor both groups of patients to see if the investigators improve the risk and/or severity of infection. Levofloxacin is commonly used in other clinical settings but has not been studied in patients with MDS or AML receiving outpatient chemotherapy (ie, chemotherapy that can be given from clinic, rather than a hospital).
STUDY OBJECTIVES: The primary objective of this trial is to demonstrate the feasibility of a pragmatic pilot trial necessary to inform our planned phase 3 trial. TRIAL DESIGN: The investigators will conduct a 75-patient multicentre randomized open-label pilot feasibility trial evaluating levofloxacin versus usual care in patients diagnosed with myelodysplastic syndrome and acute myeloid leukemia receiving outpatient therapy. The intervention group will be levofloxacin 500mg orally daily over the 90-day trial period. Patients will take the levofloxacin daily regardless of their neutrophil count. The control group will be usual care and routine antibiotic prophylaxis is not permitted. OUTCOMES: Our primary outcome will assess the feasibility of a large, multicentre trial of antibiotic prophylaxis in patients with MDS and AML at risk for infectious complications. Our primary measure of feasibility will be the ability to enroll a median of 1 patient per site per month (10 patients / month when all sites are active). SITES AND DURATION: The investigators will initially enroll patients from 10-15 sites across Canada. The expected duration of enrollment is 2 years. SIGNIFICANCE: The trial will evaluate the feasibility of studying antibiotic prophylaxis to optimize supportive care and minimize disease-related complications in patients with MDS and AML. If antibiotic prophylaxis reduces infectious complications, the results of the trial will represent a paradigm shift in how outpatients with MDS and AML are supported and will directly impact practice throughout the world. The initial infrastructure established from this feasibility study will be leveraged to create platform trial infrastructure that will function as a patient-centred learning health system to advance knowledge and improve outcomes for patients with MDS and AML.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Master platform inclusion criteria:
MYELO-CAN ABX inclusion criteria:
1. Initiation of hypomethylating agent-based chemotherapy
Exclusion Criteria:
Master platform exclusion criteria:
MYELO-CAN ABX exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Levofloxacin
Other: Usual Care
This group will receive Levofloxacin 500mg orally daily over the 90-day trial period. Patients will take the levofloxacin daily regardless of their neutrophil count.
This group will receive usual care. Routine antibiotic prophylaxis is not permitted.
Patient enrollment feasibility
Our primary measure of feasibility will be the ability to enroll a median of 1 patient per site per month (10 patients / month when all sites are active).
Time frame: 2 years
Ability to consent 30% of eligible patients
The consent rate to be adequate if 30% of eligible patients are enrolled.
Time frame: 2 years
Protocol adherence
Protocol adherence to be acceptable provided that 80% of all intended medication doses per patient are administered
Time frame: 2 years
Off-protocol prophylaxis antibiotic use
Off-protocol prophylaxis antibiotic use acceptable if \<10% in the control arm
Time frame: 2 years
Outcome completion
Outcome completion is adequate if 90% of outcomes are completed
Time frame: 2 years
Risk of infection
The risk of infection sufficient if the infectious complication event rate (primary outcome of the phase III trial) is \>30%.
Time frame: 2 years
Frequency of febrile neutropenia
Measure and report the frequency of febrile neutropenia and calculate the mean and median number of febrile neutropenic events per patient.
Time frame: 2 years
Frequency of hospitalizations due to infection
Measure the frequency of hospitalizations due to infection and calculate the mean and median number of infection-related hospitalizations per patient.
Time frame: 2 years
Number of deaths due to infection
Record the number of deaths due to infection.
Time frame: 2 years
Frequency of chemotherapy delays
Measure the frequency of chemotherapy delays of ≥1 week. Calculate the mean and median number of ≥1-week chemotherapy cycle delays per patient.
Time frame: 3 months
Frequency of chemotherapy cycles with dose reductions
Measure the frequency of chemotherapy cycles with dose reductions and calculate the mean and median number of chemotherapy cycles with dose reductions per patient.
Time frame: 3 months
Start is estimated for Feb 2027; primary completion for Apr 2028, 14 months later.
Of 74 non-industry phase 2 interventional studies under Myeloproliferative Disorders, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 118. This study's planned 14 months is below that.
Counting every sponsor, half of 87 studies reached it within 68 months; a quarter within 37 and three quarters within 111.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Feb 2027, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levofloxacin
Myeloproliferative Disorders →